Recruiting

Light therapy treatment for moderate to severe skin plaques

Plain-English translation of NCT03392337 on ClinicalTrials.gov ↗ · Source last updated January 2019 · Translation generated June 2026 · How we translate trials

Read our Psoriasis research guide →

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing narrowband ultraviolet-B phototherapy — a medical light treatment — for adults with moderate-to-severe psoriasis. You would receive light therapy sessions three times per week for 12 weeks, with the dose increasing gradually. Researchers want to see how well this treatment works and whether the benefits last over time.

While light therapy has been used for psoriasis for many years, researchers want to confirm it works well for people with more serious cases and understand how long the benefits last after treatment stops.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with chronic plaque-type psoriasis for at least 6 months
you have moderate-to-severe psoriasis covering a significant portion of your skin
you are able to attend light therapy sessions three times per week for 12 weeks and follow-up visits
you are in good overall health aside from your psoriasis

You likely don't qualify if…

you have other types of psoriasis besides plaque psoriasis, such as pustular or guttate psoriasis
you have a history of photosensitivity or severe reactions to sunlight
you have recently used certain strong psoriasis medications like biologic drugs or oral systemic treatments within the past few weeks or months
you have received other types of light therapy or phototherapy within the past 4 weeks
you have an active infection requiring antibiotics in the 2 weeks before the study begins

What participation looks like

You would visit the treatment center three times per week for 12 weeks to receive light therapy sessions. The dose of light would gradually increase during this period. After the 12-week treatment phase ends, you would return for follow-up visits every 6 weeks through week 36 so the researchers can see how well the treatment continues to work and whether the improvement lasts.

AI-generated summary from trial data · Jun 17, 2026 · Not medical advice

Trial locations(1 site)

United States

Elise Nelson, East Windsor, New Jersey